← Back to Investors

Seroba Life Sciences

Seroba Life Sciences is a Dublin-based venture capital firm focused exclusively on life sciences investments across Europe. The firm specializes in early-stage biotech, medtech, and digital health companies, with particular expertise in supporting Irish and European entrepreneurs.

Location
Dublin, Ireland
Founded
2005
AUM
€300M+
Investment Range
€2M - €15M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b

Investment Thesis

Seroba invests in European life sciences companies with differentiated technologies and strong intellectual property. They seek opportunities in therapeutics, medical devices, and diagnostics where they can add value through their deep sector expertise and extensive network of industry advisors.

Team

Partners / Managing Directors

  • Charles Fortune - Managing Partner
  • Shane Cahalane - Managing Partner
  • Fergal Naughton - Partner

Other Key Team Members

  • Daniel Gallagher - Investment Director

Focus Areas

  • Therapeutics
  • Medical Devices
  • Diagnostics
  • Digital Health
  • Drug Delivery
  • Oncology
  • Neuroscience

Notable Portfolio Companies

  • Inflazome - NLRP3 inflammasome inhibitors (acquired by Roche)
  • Nuritas - AI-driven peptide discovery
  • Shorla Oncology - Pediatric oncology drugs
  • Avectas - Cell therapy delivery

Notable Exits

  • Inflazome - Acquired (2020, acquired by Roche for up to €380M)
  • Amarin - IPO (NASDAQ: AMRN, cardiovascular therapeutics)
  • PharmaLex - Acquired (acquired by Cencora)

Sources